[{"id":"74157a34-d6de-4ba9-9962-025f2effcf7f","acronym":"ALPHABET","url":"https://clinicaltrials.gov/study/NCT05063786","created_at":"2021-10-01T11:54:26.039Z","updated_at":"2025-02-25T12:37:59.796Z","phase":"Phase 3","brief_title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","source_id_and_acronym":"NCT05063786 - ALPHABET","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-24"},{"id":"c5baf3d3-95f8-46cc-89ee-2ac65d9ade70","acronym":"","url":"https://clinicaltrials.gov/study/NCT06023641","created_at":"2023-09-05T18:12:33.949Z","updated_at":"2025-02-25T12:29:46.532Z","phase":"Phase 1/2","brief_title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","source_id_and_acronym":"NCT06023641","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • FOXO1 • MYOD1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • FOXO1 • MYOD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/13/2024","start_date":" 03/13/2024","primary_txt":" Primary completion: 10/01/2034","primary_completion_date":" 10/01/2034","study_txt":" Completion: 10/01/2037","study_completion_date":" 10/01/2037","last_update_posted":"2025-02-24"},{"id":"cce0df20-21d8-4bec-947f-b02d39935805","acronym":"ARST2031","url":"https://clinicaltrials.gov/study/NCT04994132","created_at":"2023-08-27T06:10:56.547Z","updated_at":"2025-02-25T14:08:23.955Z","phase":"Phase 3","brief_title":"A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma","source_id_and_acronym":"NCT04994132 - ARST2031","lead_sponsor":"Children's Oncology Group","biomarkers":" FOXO1","pipe":"","alterations":" ","tags":["FOXO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vincristine • dactinomycin • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-18"},{"id":"64fbfa8e-e3d5-4527-8e70-e669cf683ef4","acronym":"MOVIE","url":"https://clinicaltrials.gov/study/NCT03518606","created_at":"2021-01-18T17:19:19.354Z","updated_at":"2025-02-25T15:07:35.561Z","phase":"Phase 1/2","brief_title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03518606 - MOVIE","lead_sponsor":"UNICANCER","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 126","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 12/19/2024","study_completion_date":" 12/19/2024","last_update_posted":"2025-01-15"},{"id":"8c8ff781-f391-42de-9882-e4814d7bf8ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03887130","created_at":"2021-01-18T19:09:12.750Z","updated_at":"2024-07-02T16:35:07.040Z","phase":"Phase 2","brief_title":"Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer","source_id_and_acronym":"NCT03887130","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • docetaxel • capecitabine • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 152","initiation":"Initiation: 03/27/2007","start_date":" 03/27/2007","primary_txt":" Primary completion: 04/18/2013","primary_completion_date":" 04/18/2013","study_txt":" Completion: 04/18/2013","study_completion_date":" 04/18/2013","last_update_posted":"2024-04-30"},{"id":"94f2c520-fdab-4936-980c-693760a72522","acronym":"METEORA-II","url":"https://clinicaltrials.gov/study/NCT02954055","created_at":"2021-01-18T14:30:32.840Z","updated_at":"2024-07-02T16:35:17.646Z","phase":"Phase 2","brief_title":"MEtronomic TrEatment Option in Advanced bReast cAncer","source_id_and_acronym":"NCT02954055 - METEORA-II","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • cyclophosphamide • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 09/13/2017","start_date":" 09/13/2017","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 11/23/2022","study_completion_date":" 11/23/2022","last_update_posted":"2024-02-26"},{"id":"23e2bcb5-1612-4e8c-afcb-bd63c8997ee0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04388839","created_at":"2023-08-27T06:10:27.849Z","updated_at":"2024-07-02T16:35:18.394Z","phase":"Phase 2","brief_title":"Evolutionary Therapy for Rhabdomyosarcoma","source_id_and_acronym":"NCT04388839","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" FOXO1","pipe":"","alterations":" ","tags":["FOXO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 09/27/2020","start_date":" 09/27/2020","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-02-21"},{"id":"aa38eeda-5483-4291-b2f6-f2732467a0db","acronym":"SYSKY-2023-1016-01","url":"https://clinicaltrials.gov/study/NCT06255392","created_at":"2024-02-14T01:28:08.463Z","updated_at":"2024-07-02T16:35:19.550Z","phase":"Phase 3","brief_title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT06255392 - SYSKY-2023-1016-01","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • AiTan (rivoceranib) • capecitabine • Halaven (eribulin mesylate) • AiRuiYi (fluzoparib) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2024-02-13"},{"id":"f3babfe8-bc92-4caa-90a6-a8f28168e283","acronym":"","url":"https://clinicaltrials.gov/study/NCT05823623","created_at":"2023-04-21T15:04:29.768Z","updated_at":"2024-07-02T16:35:36.955Z","phase":"Phase 2","brief_title":"Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT05823623","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Cipterbin (inetetamab) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/13/2022","start_date":" 02/13/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-09-14"},{"id":"fa87048f-420f-406b-8c99-62a5161df0e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015126","created_at":"2023-08-29T16:10:04.804Z","updated_at":"2024-07-02T16:35:38.733Z","phase":"","brief_title":"Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT06015126","lead_sponsor":"Yan Xue","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-08-29"},{"id":"41d8c22d-3b0f-482a-9636-981a31cd84cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05826964","created_at":"2023-04-24T14:04:07.490Z","updated_at":"2024-07-02T16:35:39.425Z","phase":"Phase 2","brief_title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","source_id_and_acronym":"NCT05826964","lead_sponsor":"University of Miami","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • tamoxifen • capecitabine • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • anastrozole • exemestane • Orserdu (elacestrant) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 06/12/2023","start_date":" 06/12/2023","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2029","study_completion_date":" 07/31/2029","last_update_posted":"2023-08-21"},{"id":"d160a602-9e58-45a8-8e2b-46a9f6adfadd","acronym":"VEX","url":"https://clinicaltrials.gov/study/NCT04304352","created_at":"2021-01-18T20:52:33.096Z","updated_at":"2024-07-02T16:35:44.461Z","phase":"Phase 2","brief_title":"Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT04304352 - VEX","lead_sponsor":"European Institute of Oncology","biomarkers":" ER","pipe":" | ","alterations":" HER-2 overexpression","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 07/29/2011","start_date":" 07/29/2011","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-06-28"},{"id":"035efbd5-6fee-46bb-9159-ec783a6144a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05747326","created_at":"2023-02-28T13:01:22.187Z","updated_at":"2024-07-02T16:35:54.527Z","phase":"Phase 2","brief_title":"Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer","source_id_and_acronym":"NCT05747326","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2023-02-28"},{"id":"93a670e0-f4fc-4382-90bd-b0bb32dabc11","acronym":"","url":"https://clinicaltrials.gov/study/NCT02139904","created_at":"2021-01-18T09:56:08.432Z","updated_at":"2024-07-02T16:36:23.174Z","phase":"Phase 2","brief_title":"Vinorelbine in Mesothelioma","source_id_and_acronym":"NCT02139904","lead_sponsor":"Wales Cancer Trials Unit","biomarkers":" BRCA1","pipe":"","alterations":" ","tags":["BRCA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 154","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 03/17/2021","primary_completion_date":" 03/17/2021","study_txt":" Completion: 03/17/2021","study_completion_date":" 03/17/2021","last_update_posted":"2021-10-12"},{"id":"aa064749-2966-4885-b3cb-bf7feeac3424","acronym":"OVIMA-1210","url":"https://clinicaltrials.gov/study/NCT02197637","created_at":"2021-01-18T10:16:35.601Z","updated_at":"2024-07-02T16:36:38.543Z","phase":"Phase 2","brief_title":"Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma","source_id_and_acronym":"NCT02197637 - OVIMA-1210","lead_sponsor":"Centre Oscar Lambret","biomarkers":" ABCB1 • CYP3A5","pipe":"","alterations":" ","tags":["ABCB1 • CYP3A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2020-11-18"},{"id":"b9048f19-4bc9-47a3-ac2f-1e80c71f3e2d","acronym":"ORCHID","url":"https://clinicaltrials.gov/study/NCT04296162","created_at":"2021-01-18T20:50:37.051Z","updated_at":"2024-07-02T16:36:49.154Z","phase":"Phase 2","brief_title":"Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)","source_id_and_acronym":"NCT04296162 - ORCHID","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Unknown status","enrollment":" Enrollment 178","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 05/30/2021","primary_completion_date":" 05/30/2021","study_txt":" Completion: 05/30/2021","study_completion_date":" 05/30/2021","last_update_posted":"2020-03-05"},{"id":"22ded344-8523-43c1-ba10-387b228da5a6","acronym":"ADJUVANT","url":"https://clinicaltrials.gov/study/NCT01405079","created_at":"2021-01-17T17:12:26.409Z","updated_at":"2024-07-02T16:36:49.859Z","phase":"Phase 3","brief_title":"Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation","source_id_and_acronym":"NCT01405079 - ADJUVANT","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gefitinib • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Unknown status","enrollment":" Enrollment 222","initiation":"Initiation: 09/19/2011","start_date":" 09/19/2011","primary_txt":" Primary completion: 03/01/2017","primary_completion_date":" 03/01/2017","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-02-18"},{"id":"cf9fdacd-ec40-45b0-b6df-79aeed47d866","acronym":"VINORELBINA","url":"https://clinicaltrials.gov/study/NCT04208854","created_at":"2021-01-18T20:29:53.211Z","updated_at":"2024-07-02T16:36:52.078Z","phase":"","brief_title":"Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04208854 - VINORELBINA","lead_sponsor":"International Group of Endovascular Oncology","biomarkers":" EGFR • PD-L1","pipe":"","alterations":" ","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 04/18/2018","start_date":" 04/18/2018","primary_txt":" Primary completion: 04/18/2020","primary_completion_date":" 04/18/2020","study_txt":" Completion: 05/18/2020","study_completion_date":" 05/18/2020","last_update_posted":"2019-12-26"},{"id":"7d71ec35-c683-4a3b-b2da-6eb1eb19218c","acronym":"VinoMetro","url":"https://clinicaltrials.gov/study/NCT03007992","created_at":"2021-01-18T14:47:55.771Z","updated_at":"2024-07-02T16:36:57.037Z","phase":"Phase 2","brief_title":"Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer","source_id_and_acronym":"NCT03007992 - VinoMetro","lead_sponsor":"Johannes Gutenberg University Mainz","biomarkers":" HER-2 • PGR • ISG20","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PGR • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 03/02/2019","primary_completion_date":" 03/02/2019","study_txt":" Completion: 03/02/2019","study_completion_date":" 03/02/2019","last_update_posted":"2019-08-12"},{"id":"350aaae4-5f3f-419a-8445-e7ac639da3ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT04021992","created_at":"2021-01-18T19:44:52.961Z","updated_at":"2024-07-02T16:36:57.324Z","phase":"Phase 2","brief_title":"GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL","source_id_and_acronym":"NCT04021992","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/15/2019","start_date":" 07/15/2019","primary_txt":" Primary completion: 07/15/2023","primary_completion_date":" 07/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2019-08-06"},{"id":"13b3cc24-e05f-440a-bbc0-42f6884ffa3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02768415","created_at":"2021-01-18T13:34:33.900Z","updated_at":"2024-07-02T16:36:58.799Z","phase":"Phase 2","brief_title":"Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer","source_id_and_acronym":"NCT02768415","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":"","study_completion_date":"","last_update_posted":"2019-06-19"},{"id":"d4db6f6e-eca2-4ce1-a98e-be2c558ca88b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00912275","created_at":"2021-01-18T03:31:37.090Z","updated_at":"2025-02-25T13:14:57.648Z","phase":"Phase 1/2","brief_title":"Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer","source_id_and_acronym":"NCT00912275","lead_sponsor":"National Taiwan University Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 11/24/2008","start_date":" 11/24/2008","primary_txt":" Primary completion: 03/31/2015","primary_completion_date":" 03/31/2015","study_txt":" Completion: 07/07/2017","study_completion_date":" 07/07/2017","last_update_posted":"2019-05-06"},{"id":"60c0b278-7d34-4de9-8a2b-0f8d9eaf72de","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854617","created_at":"2021-01-18T19:01:27.702Z","updated_at":"2024-07-02T16:37:02.449Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer","source_id_and_acronym":"NCT03854617","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 02/20/2019","start_date":" 02/20/2019","primary_txt":" Primary completion: 12/20/2021","primary_completion_date":" 12/20/2021","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2019-02-26"},{"id":"263ec36e-c67a-4631-a022-75159c2462b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703427","created_at":"2021-01-18T18:08:54.819Z","updated_at":"2024-07-02T16:37:06.179Z","phase":"Phase 2","brief_title":"Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy","source_id_and_acronym":"NCT03703427","lead_sponsor":"Zhiyong Yu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2018-10-12"}]